View Post

In DRESS/DIHS, early treatment with high dose steroids may suppress HHV-6; late treatment may prolong viremia

In All, Drug Hypersensitivity, Transplant Complications by Kristin Loomis

High dose steroids given in the first week appears to prevent HHV-6 reactivation in DRESS/DIHS patients by suppressing T-cell activation and serum interleukin-2 receptor (sIL-2R) levels. In contrast, a late start of steroid therapy resulted in a persistently high viral load for at least three weeks.

View Post

HHV-6B lung infection doubles the mortality rate of transplant patients with respiratory disease

In All, Lung Disease, Transplant Complications by Kristin Loomis

Investigators at the Fred Hutchinson Cancer Research Center and University of Washington in Seattle found that HHV-6B in lung fluid of bone marrow transplant recipients with pneumonia is associated with a 2-fold increased risk of death. Importantly, HHV-6B positive patients who were treated with an antiviral had a 60% lower risk of death.